Jenburkt Pharmaceuticals credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
0.02.00.02.4
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−53.1−22.7−79.2−51.4
0.00×0.05×0.00×0.09×
−1.32×−0.61×−2.60×−1.85×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JENBURPH₹872.30

Jenburkt Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Total Debt2.40.02.00.0
Net Debt-51.4-79.2-22.7-53.1
Total Debt/EBITDA0.090.000.050.00
Net Debt/EBITDA-1.85-2.60-0.61-1.32
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.